AYTU BIOPHARMA, INC 8-K

What Happened
AYTU BioPharma, Inc. (AYTU) announced its fiscal 2026 second-quarter operational and financial results via a press release dated February 3, 2026 and filed an 8-K to disclose the announcement. The company scheduled a conference call and live audio webcast for February 3, 2026 at 4:30 p.m. Eastern to discuss the results and answer questions. The press release was furnished as Exhibit 99.1 to the Form 8-K.

Key Details

• Press release announcing Q2 fiscal 2026 operational and financial results issued on February 3, 2026.
• Conference call and live webcast scheduled for February 3, 2026 at 4:30 p.m. Eastern; access via the company website and telephone (live and replay).
• A replay will be made available after the call on AYTU’s website and by phone, but replay availability is at the company’s discretion and may be discontinued.
• The press release is furnished as Exhibit 99.1 and is not "filed" under Section 18 of the Exchange Act nor automatically incorporated by reference into other filings.

Why It Matters
This 8-K signals AYTU’s release of its latest quarterly results and provides investors an opportunity to hear management’s commentary and Q&A on performance, trends, and near-term plans. Because the 8-K itself does not include the financial line items, investors should review the press release and listen to (or replay) the webcast for the full earnings details (revenue, earnings, cash flow, and management discussion). Note that replay access may be limited at the company’s discretion.